Thoracic Oncology Program
Experience, Surgical Excellence, and Outstanding Multidisciplinary Care
Gene Breakthroughs Spark Revolution in Treatment

Trever G. Bivona, M.D., Ph.D.(standing) tells the Wall Street Journal how precision medicine is leading to gene breakthroughs and a revolution in the treatment of lung cancer, the goal - pairing a drug with the specific mutation fueling a patientメs disease. (Also pictured ᅠBivona Lab research specialist Elton Chan).

Gene Breakthroughs Spark a Revolution in Cancer Treatment (Wall Street Journal)

New Lung Cancer Test More Accurately Predicts Survival
Jablons Talk On Gene Final2

In the two largest ever clinical studies on the molecular genetics of lung cancer, an international team, led by thoracic surgeonsᅠDavid M. Jablons, M.D.ᅠ(left),ᅠMichael Mann, M.D.,ᅠand Johannes Kratz, M.D., a former surgical resident,ᅠshowed a molecular test better predicted death from early-stage lung cancer than conventional staging.

Test Guides Treatment for Earliest-Stage Patients
_DSC0373

A molecular test developed by physician-scientists at UCSF may better predict post-operative mortality in early-stage lung cancer patients. Building on earlier work, the group identified a group of post-operative patients withᅠthe earliest stage of lung cancerᅠwho had a high likelihood of recurrence.

Thoracic Oncology Logo Final -PrintLung cancer is the leading cause of cancer death worldwide and the Thoracic Oncology Program is poised to conquer it. UCSF provides state-of-the-art care to patients with lung cancer, mesothelioma, esophageal cancer, sarcoma and cancer that has metastasized to the chest. The program is led by David M. Jablons, M.D., Chief of the Section of General Thoracic Surgery and Program Leader of the Thoracic Oncology Program. Patients receive treatment from a dedicated multidisciplinary team of specialists. At UCSF, one of the world's leading biomedical research centers, patients also have access to clinical trials for promising new drugs.